Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Auxilium Signs Sobi As Pfizer Replacement In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

The maker of Xiaflex/Xiapex has found a new commercialization partner in the EU after its first partnership fell apart due to disappointing sales of the drug in those territories.

You may also be interested in...



Pending EU Approval Of Eloctate, Sobi Opts In To Second Hemophilia Program With Biogen

Sobi also gets two oral formulations of Orfadin for the rare genetic disorder HT-1 and is starting over with a new candidate in a collaboration with Affibody.

Auxilium Revamps Commercial Strategy For Xiaflex

The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel